Nichi-Iko Pharmaceutical Catalyst Calendar
Proactively evaluate Nichi-Iko Pharmaceutical Co Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Nichi-Iko Pharmaceutical Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 31 Dec 2021 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 30 Sep 2021 | Phase I/II Trial Completion | Kangen Pharmaceuticals Co Ltd; Nichi-Iko Pharmaceutical Co Ltd | 4541 | NI-03 | Central Nervous System; Gastrointestinal | Pancreatitis; Pancreatitis Pain | Clinical Trial Registry |
| 30 Sep 2021 | Phase II/III Trial Results | AIDS Clinical Trials Group; AstraZeneca Plc; Brii Biosciences Ltd; Bristol-Myers Squibb Co; Eli Lilly and Co; InnoPharma Srl; Nichi-Iko Pharmaceutical Co Ltd; Pinnacle Clinical Research Center; PPD Inc; SAB Biotherapeutics Inc; Sagent Pharmaceuticals Inc; Science 37 Inc; Synairgen Plc; The National Institute of Allergy and Infectious Diseases; U.S. National Institutes of Health | 2137; 4541; AZN; BMY; LLY; SABS; SNG | amubarvimab; bamlanivimab; camostat mesilate; casirivimab + imdevimab; cilgavimab + tixagevimab; crexavibart + ogalvibart; interferon beta-1a; romlusevimab; SAB-185 | Infectious Disease | Coronavirus Disease 2019 (COVID-19) | Company Presentation |
| 30 Apr 2021 | Phase II Trial Completion | Chugai Pharmaceutical Co Ltd; Elmed Eisai Co Ltd; Japan Agency for Medical Research and Development; School of Medicine Keio University | 4519 | docetaxel; trastuzumab | Oncology | Extramammary Paget Disease (EMPD) | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer